Vyznova cell therapy received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for the treatment of bullous keratopathy, according to a press release from Aurion Biotech.
Aurion Biotech said this is the first regulatory approval in the world for an allogeneic cell therapy for corneal endothelial disease.
Healio/OSN spoke with Edward J. Holland, MD, the director of cornea services at Cincinnati Eye Institute and a professor of ophthalmology at the University of Cincinnati, about how the approval will transform cornea treatment and benefit ophthalmologists.